Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 148 clinical trials
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

) grade 1-3a *1,2 In patients with diffuse large B-cell lymphoma (DLBCL) *1,2 In patients with mantle cell lymphoma (MCL) that has relapsed after or is refractory to a BTK inhibitor

btk inhibitor
marginal zone lymphoma
measurable disease
alkylating agent
renal function
  • 43 views
  • 02 Aug, 2021
  • 85 locations
An Open-label Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

  • 0 views
  • 13 Feb, 2021
  • 13 locations
CART-19 Immunotherapy in Mantle Cell Lymphoma

Patients receive anti-CD19-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells over a period of 4 or 5 consecutive days in an escalating dose. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 10 …

fludarabine
remission
apheresis
mantle cell lymphoma
monoclonal antibodies
  • 77 views
  • 08 Nov, 2020
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

This phase II trial studies how well acalabrutinib works in treating patients with mantle cell lymphoma that cannot tolerate ibrutinib. Acalabrutinib may stop the growth of cancer cells by

remission
measurable disease
ibrutinib
acalabrutinib
neutrophil count
  • 0 views
  • 27 Jan, 2021
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

-CHOP in patients with previously untreated mantle cell lymphoma prior to autologous stem cell transplantation. All patients will receive six cycles of R-CHOP chemotherapy together with continuous

cell transplantation
bendamustine
remission
acalabrutinib
r-chop
  • 0 views
  • 29 Jun, 2021
  • 3 locations
Trial of Bortezomib Cytarabine and Dexamethasone in Mantle Cell Lymphoma

The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of

cytarabine
neutrophil count
refractory mantle cell lymphoma
renal function tests
dexamethasone
  • 8 views
  • 21 Jan, 2021
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate

btk inhibitor
immunohistochemistry
measurable disease
ibrutinib
hepatitis b surface antigen
  • 23 views
  • 30 Jul, 2021
  • 11 locations
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL

zanubrutinib for newly-diagnosed Mantle Cell Lymphoma (MCL).

TP53
cytarabine
rituximab
mantle cell lymphoma
oxaliplatin
  • 0 views
  • 02 Jun, 2021
  • 3 locations
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

This phase II trial studies how well ibrutinib works in treating participants with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

remission
measurable disease
ibrutinib
cytopenia
TP53
  • 0 views
  • 25 Jan, 2021
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle cell lymphoma

btk inhibitor
acalabrutinib
neutrophil count
cyclin d1
mantle cell lymphoma
  • 102 views
  • 28 May, 2021
  • 4 locations